Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON ‐1 Study

Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

(2018) Ajit Suri et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

(2018) Yan Ji et al.   CTS-Clinical and Translational Science

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies

(2017) Hong Li et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

(2017) H Miles Prince et al.   LANCET

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

(2017) C A van der Weyden et al.   Blood Cancer Journal

Drug Development of Therapeutic Monoclonal Antibodies

(2016) Diane R. Mould et al.   BIODRUGS

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment

(2016) Baiteng Zhao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

(2016) Anna Alperovich et al.   CANCER JOURNAL

Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

(2016) K Venkatakrishnan et al.   CTS-Clinical and Translational Science

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities

(2015) K Venkatakrishnan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

(2014) Valérie F. Cosson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

(2014) Michinori Ogura et al.   CANCER SCIENCE

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

(2013) Anas Younes et al.   LANCET ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

(2011) M. A. Fanale et al.   CLINICAL CANCER RESEARCH

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer

(2011) Manish Gupta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE